SA523441083B1 - أحماض بيرازولو بيبريدين كربوكسيليك تحمل بدائل - Google Patents
أحماض بيرازولو بيبريدين كربوكسيليك تحمل بدائلInfo
- Publication number
- SA523441083B1 SA523441083B1 SA523441083A SA523441083A SA523441083B1 SA 523441083 B1 SA523441083 B1 SA 523441083B1 SA 523441083 A SA523441083 A SA 523441083A SA 523441083 A SA523441083 A SA 523441083A SA 523441083 B1 SA523441083 B1 SA 523441083B1
- Authority
- SA
- Saudi Arabia
- Prior art keywords
- diseases
- heart
- ejection fraction
- heart failure
- disease
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Neurosurgery (AREA)
- Hospice & Palliative Care (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Pulmonology (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Hydrogenated Pyridines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20213020 | 2020-12-10 | ||
| PCT/EP2021/084987 WO2022122914A1 (en) | 2020-12-10 | 2021-12-09 | Substituted pyrazolo piperidine carboxylic acids |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SA523441083B1 true SA523441083B1 (ar) | 2025-06-12 |
Family
ID=73793025
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SA523441083A SA523441083B1 (ar) | 2020-12-10 | 2023-06-07 | أحماض بيرازولو بيبريدين كربوكسيليك تحمل بدائل |
Country Status (31)
| Country | Link |
|---|---|
| US (1) | US20240051935A1 (https=) |
| EP (1) | EP4259617B1 (https=) |
| JP (1) | JP2023552583A (https=) |
| KR (1) | KR20230118144A (https=) |
| CN (1) | CN116710439A (https=) |
| AR (1) | AR124297A1 (https=) |
| AU (1) | AU2021393988A1 (https=) |
| CA (1) | CA3204495A1 (https=) |
| CL (1) | CL2023001632A1 (https=) |
| CO (1) | CO2023007335A2 (https=) |
| CR (1) | CR20230242A (https=) |
| DK (1) | DK4259617T3 (https=) |
| DO (1) | DOP2023000115A (https=) |
| EC (1) | ECSP23040828A (https=) |
| ES (1) | ES2997117T3 (https=) |
| FI (1) | FI4259617T3 (https=) |
| GE (2) | GEAP202316287A (https=) |
| HR (1) | HRP20241543T1 (https=) |
| HU (1) | HUE069255T2 (https=) |
| IL (1) | IL303296A (https=) |
| JO (1) | JOP20230132A1 (https=) |
| LT (1) | LT4259617T (https=) |
| MX (1) | MX2023006903A (https=) |
| PE (1) | PE20231501A1 (https=) |
| PL (1) | PL4259617T3 (https=) |
| PT (1) | PT4259617T (https=) |
| RS (1) | RS66294B1 (https=) |
| SA (1) | SA523441083B1 (https=) |
| SI (1) | SI4259617T1 (https=) |
| TW (1) | TW202237589A (https=) |
| WO (1) | WO2022122914A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4011873A1 (en) * | 2020-12-10 | 2022-06-15 | Bayer Aktiengesellschaft | Substituted pyrazolo piperidine carboxylic acids |
| EP4011874A1 (en) * | 2020-12-10 | 2022-06-15 | Bayer Aktiengesellschaft | Substituted pyrazolo piperidine carboxylic acids |
| EP4536205A1 (en) | 2022-06-09 | 2025-04-16 | Bayer Aktiengesellschaft | Soluble guanylate cyclase activators for use in the treatment of heart failure with preserved ejection fraction in women |
| JP2026504406A (ja) * | 2023-01-31 | 2026-02-05 | インビボサイエンシーズ インコーポレイテッド | 駆出率保持型心不全（ＨＦｐＥＦ）の治療に関するシステムおよび方法 |
| WO2025067414A1 (zh) * | 2023-09-27 | 2025-04-03 | 海思科医药集团股份有限公司 | 吡唑羧酸衍生物及其在医药上的应用 |
| WO2025162280A1 (zh) * | 2024-01-30 | 2025-08-07 | 海思科医药集团股份有限公司 | 吡唑羧酸衍生物及其在医药上的应用 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19834047A1 (de) | 1998-07-29 | 2000-02-03 | Bayer Ag | Substituierte Pyrazolderivate |
| DE19834044A1 (de) | 1998-07-29 | 2000-02-03 | Bayer Ag | Neue substituierte Pyrazolderivate |
| DE19943634A1 (de) | 1999-09-13 | 2001-04-12 | Bayer Ag | Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften |
| DE19943639A1 (de) | 1999-09-13 | 2001-03-15 | Bayer Ag | Dicarbonsäurederivate mit neuartigen pharmazeutischen Eigenschaften |
| DE19943635A1 (de) | 1999-09-13 | 2001-03-15 | Bayer Ag | Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften |
| DE19943636A1 (de) | 1999-09-13 | 2001-03-15 | Bayer Ag | Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften |
| AR031176A1 (es) | 2000-11-22 | 2003-09-10 | Bayer Ag | Nuevos derivados de pirazolpiridina sustituidos con piridina |
| DE10110749A1 (de) | 2001-03-07 | 2002-09-12 | Bayer Ag | Substituierte Aminodicarbonsäurederivate |
| DE10110750A1 (de) | 2001-03-07 | 2002-09-12 | Bayer Ag | Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften |
| DE10220570A1 (de) | 2002-05-08 | 2003-11-20 | Bayer Ag | Carbamat-substituierte Pyrazolopyridine |
| KR20100059952A (ko) * | 2007-09-06 | 2010-06-04 | 머크 샤프 앤드 돔 코포레이션 | 가용성 구아닐레이트 사이클라제 활성제 |
| DE102010001064A1 (de) | 2009-03-18 | 2010-09-23 | Bayer Schering Pharma Aktiengesellschaft | Substituierte 2-Acetamido-5-Aryl-1,2,4-triazolone und deren Verwendung |
| EA023221B1 (ru) | 2010-02-27 | 2016-05-31 | Байер Интеллектуэль Проперти Гмбх | СВЯЗАННЫЕ БИС-АРИЛЬНЫЕ АРИЛ-ТРИАЗОЛОНЫ, СПОСОБЫ ИХ ПОЛУЧЕНИЯ, ИХ ПРИМЕНЕНИЕ, ЛЕКАРСТВЕННОЕ СРЕДСТВО НА ИХ ОСНОВЕ И ДВОЙНОЙ АНТАГОНИСТ V1a/V2-РЕЦЕПТОРОВ |
| DE102010021637A1 (de) | 2010-05-26 | 2011-12-01 | Bayer Schering Pharma Aktiengesellschaft | Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung |
| PE20130779A1 (es) | 2010-07-09 | 2013-06-21 | Bayer Ip Gmbh | Pirimidinas y triazinas condensadas y su uso |
| DE102010040233A1 (de) | 2010-09-03 | 2012-03-08 | Bayer Schering Pharma Aktiengesellschaft | Bicyclische Aza-Heterocyclen und ihre Verwendung |
| EP2632551B1 (en) * | 2010-10-28 | 2016-07-06 | Merck Sharp & Dohme Corp. | Soluble guanylate cyclase activators |
| DE102010043379A1 (de) | 2010-11-04 | 2012-05-10 | Bayer Schering Pharma Aktiengesellschaft | Substituierte 6-Fluor-1H-Pyrazolo[4,3-b]pyridine und ihre Verwendung |
| DE102011007272A1 (de) | 2011-04-13 | 2012-10-18 | Bayer Pharma Aktiengesellschaft | Verzweigte 3-Phenylpropionsäure-Derivate und ihre Verwendung |
| ES2748798T3 (es) * | 2012-09-07 | 2020-03-18 | Boehringer Ingelheim Int | Alcoxi pirazoles como activadores de la guanilato ciclasa soluble |
| WO2015095515A1 (en) * | 2013-12-20 | 2015-06-25 | Novartis Ag | Sgc activators for the treatment of glaucoma |
| UA121558C2 (uk) | 2014-11-03 | 2020-06-25 | Баєр Фарма Актіенгезеллшафт | Гідроксіалкілзаміщені фенілтриазольні похідні та їх застосування |
| GB201705263D0 (en) * | 2017-03-31 | 2017-05-17 | Probiodrug Ag | Novel inhibitors |
| JP7458683B2 (ja) * | 2020-12-10 | 2024-04-01 | バイエル・アクチエンゲゼルシヤフト | 眼科疾患の治療のためのｓＧＣ活性化剤の使用 |
| CN116829545A (zh) * | 2020-12-10 | 2023-09-29 | 拜耳公司 | 取代的吡唑基哌啶羧酸 |
-
2021
- 2021-12-09 EP EP21823605.7A patent/EP4259617B1/en active Active
- 2021-12-09 HU HUE21823605A patent/HUE069255T2/hu unknown
- 2021-12-09 PT PT218236057T patent/PT4259617T/pt unknown
- 2021-12-09 TW TW110146019A patent/TW202237589A/zh unknown
- 2021-12-09 JP JP2023535063A patent/JP2023552583A/ja active Pending
- 2021-12-09 ES ES21823605T patent/ES2997117T3/es active Active
- 2021-12-09 HR HRP20241543TT patent/HRP20241543T1/hr unknown
- 2021-12-09 US US18/256,647 patent/US20240051935A1/en active Pending
- 2021-12-09 CA CA3204495A patent/CA3204495A1/en active Pending
- 2021-12-09 MX MX2023006903A patent/MX2023006903A/es unknown
- 2021-12-09 WO PCT/EP2021/084987 patent/WO2022122914A1/en not_active Ceased
- 2021-12-09 DK DK21823605.7T patent/DK4259617T3/da active
- 2021-12-09 AU AU2021393988A patent/AU2021393988A1/en active Pending
- 2021-12-09 GE GEAP202316287A patent/GEAP202316287A/en unknown
- 2021-12-09 RS RS20241357A patent/RS66294B1/sr unknown
- 2021-12-09 PL PL21823605.7T patent/PL4259617T3/pl unknown
- 2021-12-09 PE PE2023001808A patent/PE20231501A1/es unknown
- 2021-12-09 SI SI202130234T patent/SI4259617T1/sl unknown
- 2021-12-09 CN CN202180081892.0A patent/CN116710439A/zh active Pending
- 2021-12-09 AR ARP210103422A patent/AR124297A1/es unknown
- 2021-12-09 LT LTEPPCT/EP2021/084987T patent/LT4259617T/lt unknown
- 2021-12-09 IL IL303296A patent/IL303296A/en unknown
- 2021-12-09 FI FIEP21823605.7T patent/FI4259617T3/fi active
- 2021-12-09 CR CR20230242A patent/CR20230242A/es unknown
- 2021-12-09 GE GEAP202116287A patent/GEP20247649B/en unknown
- 2021-12-09 KR KR1020237022818A patent/KR20230118144A/ko active Pending
-
2023
- 2023-06-01 EC ECSENADI202340828A patent/ECSP23040828A/es unknown
- 2023-06-02 CO CONC2023/0007335A patent/CO2023007335A2/es unknown
- 2023-06-06 CL CL2023001632A patent/CL2023001632A1/es unknown
- 2023-06-07 DO DO2023000115A patent/DOP2023000115A/es unknown
- 2023-06-07 SA SA523441083A patent/SA523441083B1/ar unknown
- 2023-06-08 JO JOJO/P/2023/0132A patent/JOP20230132A1/ar unknown
Also Published As
| Publication number | Publication date |
|---|---|
| GEAP202316287A (en) | 2023-09-11 |
| ECSP23040828A (es) | 2023-07-31 |
| HUE069255T2 (hu) | 2025-02-28 |
| SI4259617T1 (sl) | 2025-02-28 |
| PL4259617T3 (pl) | 2025-03-17 |
| FI4259617T3 (fi) | 2024-11-27 |
| DK4259617T3 (da) | 2024-12-09 |
| CN116710439A (zh) | 2023-09-05 |
| JOP20230132A1 (ar) | 2023-06-08 |
| TW202237589A (zh) | 2022-10-01 |
| MX2023006903A (es) | 2023-06-26 |
| GEP20247649B (en) | 2024-07-25 |
| CL2023001632A1 (es) | 2023-11-10 |
| AU2021393988A1 (en) | 2023-06-22 |
| AU2021393988A9 (en) | 2024-09-19 |
| ES2997117T3 (en) | 2025-02-14 |
| CO2023007335A2 (es) | 2023-06-09 |
| CR20230242A (es) | 2023-07-19 |
| PT4259617T (pt) | 2024-12-05 |
| PE20231501A1 (es) | 2023-09-26 |
| IL303296A (en) | 2023-07-01 |
| AR124297A1 (es) | 2023-03-15 |
| JP2023552583A (ja) | 2023-12-18 |
| US20240051935A1 (en) | 2024-02-15 |
| LT4259617T (lt) | 2024-12-10 |
| EP4259617B1 (en) | 2024-10-23 |
| EP4259617A1 (en) | 2023-10-18 |
| RS66294B1 (sr) | 2025-01-31 |
| WO2022122914A1 (en) | 2022-06-16 |
| HRP20241543T1 (hr) | 2025-01-03 |
| CA3204495A1 (en) | 2022-06-16 |
| KR20230118144A (ko) | 2023-08-10 |
| DOP2023000115A (es) | 2023-07-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SA523441083B1 (ar) | أحماض بيرازولو بيبريدين كربوكسيليك تحمل بدائل | |
| JOP20230130A1 (ar) | أحماض بيرازولو بيبريدين كربوكسيليك تحمل بدائل | |
| MX2015003641A (es) | Una mezcla de acidos carboxilicos, especificamente acido citrico, acido succinico, acido fumarico, acido malico, y su uso para el tratamiento de pacientes con insuficiencia renal cronica, insuficiencia renal aguda, hepatopatias agudas o cronicas que cursen con hiperamonemia, enfermedades congenitas con ateraciones enzimaticas en el ciclo de la urea, asi como condiciones clínicas que cursen con balance notrogenado negativo. | |
| JOP20200098A1 (ar) | طرق علاج الفشل القلبي مع كسر قذفي منخفض بواسطة داباجليفلوزين | |
| JOP20210039B1 (ar) | مركبات بيريدين 6،2 - ديامينو | |
| JP2016511238A5 (https=) | ||
| Monardo et al. | Updates on hemodialysis techniques with a common denominator: The personalization of the dialytic therapy | |
| Honore et al. | The big bang of hemofiltration: the beginning of a new era in the third millennium for extra-corporeal blood purification! | |
| Yang et al. | Is initiating NOACs for atrial arrhythmias safe in adults with congenital heart disease? | |
| Schaefer et al. | Bleeding and thrombotic events in post-cardiotomy extracorporeal life support | |
| Unarokov et al. | Comparison of sustained low‐efficiency dialysis with acetate‐free and acetate‐containing bicarbonate dialysate in unstable patients | |
| CN103074319B (zh) | 一种尿激酶与人尿胰蛋白酶抑制剂的分离方法 | |
| EA201100243A1 (ru) | Композиции для лечения розацеи | |
| SADEGHPOUR et al. | MODIFIED ULTRAFILTRATION IN CORONARY ARTERY BYPASS GRAFTING: ARANDOMIZED, DOUBLE-BLINDED, CONTROLLED CLINICAL TRIAL | |
| CN105560460A (zh) | 用于治疗高血压的山楂决明汤 | |
| Epstein et al. | A Comparison of the Efficacy of Patiromer Plus RAAS Inhibitor Therapy in Patients with CKD and Diabetes to a Cohort of Patients Not Using Patiromer: A Real-World Analysis Using Propensity Score Matching: PO2369 | |
| MX2022002993A (es) | Rebamipida para usarse en la prevencion y/o tratamiento de la rigidez arterial. | |
| Umeda et al. | Metformin associated lactic acidosis | |
| Figurek et al. | What is the place of sclerostin in chronic kidney disease, atherosclerosis, and ageing? | |
| Woo et al. | The incidence of IgA nephropathy is associated with socioeconomic deprivation | |
| Ghatak | Methanol toxicity: case report | |
| Toom et al. | A52 CRITICAL CARE CASE REPORTS: ADULT AND PEDIATRIC SEPSIS AND ICU INFECTIONS: Bilateral Lower Extremity Ischemia With Palpable Pulses Due To Disseminated Intravascular Coagulation Secondary To Sepsis-A Cause Often Ignored! | |
| TH1801000840A (th) | เกลือของตัวยับยั้งlsd1 | |
| Yoon | Cisatracurium besilate | |
| CN104586884A (zh) | 新型血液透析浓缩液 |